Company Overview
Pacific Biosciences of California, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry where it designs, develops, and manufactures sequencing solutions intended to resolve genetically complex problems. The company's product portfolio includes sequencing systems, consumable products utilizing single molecule real-time (SMRT) technology, long-read sequencing capabilities, and various reagent kits. As of the latest available data, the company holds a market capitalization of $419.78 million and employs 485 individuals across its operations. These financial figures, including a trailing twelve-month revenue of $160.00 million, indicate that Pacific Biosciences functions as a mid-sized enterprise within the specialized biotechnology landscape. While the market cap suggests a significant valuation relative to its revenue base, the scale of operations defined by the employee count and revenue generation points to an entity that is still establishing its dominance in a niche market rather than being a fully mature market leader with massive scale.
Financial Health
The company reported revenue of $160.00 million for the trailing twelve months, yet it posted a net income of -$546,376,000 and an EBITDA of -$169,226,000. The substantial gap between the positive revenue of $160.00 million and the negative net income reveals a cost structure where operating expenses, likely driven by high R&D and manufacturing costs associated with sequencing technology, far exceed gross profits. Despite the negative net income, the company generated free cash flow of $97.55 million, which provides a critical buffer for financial flexibility and indicates that the business model can generate cash from operations even while posting accounting losses. Profitability metrics further highlight these structural challenges, with a gross margin of 34.3%, an operating margin of -134.5%, and a profit margin of 0.0%. The negative operating margin suggests that operating expenses are disproportionately high relative to revenue, while the zero profit margin confirms that the company has not yet achieved overall net profitability. On the balance sheet, the company holds $279.51 million in cash against $702.42 million in debt, resulting in a debt-to-equity ratio of 13131.84, which characterizes a highly leveraged position rather than a conservative one. Liquidity is supported by a current ratio of 5.15, indicating that the company possesses more than five times the current assets necessary to cover its short-term liabilities. Return metrics reflect the financial strain, with a return on equity of -213.5% and a return on assets of -33.7%, signaling that management has not yet been effective in generating returns for shareholders or utilizing assets to produce profit.
Valuation Assessment
Valuation multiples for Pacific Biosciences present a complex picture, featuring a P/E ratio (TTM) of N/A and a forward P/E of -3.37. The negative forward P/E and the absence of a trailing P/E imply that the market is pricing the stock based on future expectations rather than current earnings, as the negative forward multiple suggests analysts anticipate earnings that may still be negative or are adjusting the valuation model for the specific loss structure. The price-to-book ratio stands at 77.22, indicating a significant market premium over the company's book value, which often occurs in technology sectors where intangible assets like intellectual property are undervalued on the balance sheet. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 2.62 and an EV/EBITDA of -4.98, suggesting that investors are willing to pay a premium for revenue generation despite the negative earnings yield. Price action has been volatile, with a 52-week high of $2.73 and a 52-week low of $0.85, meaning the current price sits significantly below the yearly peak but well above the yearly trough. The stock exhibits a beta of 2.30, which indicates that the share price is highly volatile and tends to fluctuate with much greater intensity than the broader market.
Growth & Income
Revenue growth for the year over year was 13.8%, while earnings growth is listed as N/A due to the company's historical losses. The divergence between positive revenue growth and the lack of earnings growth highlights a phase of reinvestment where top-line expansion is prioritized over immediate profitability. Regarding income, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available earnings and cash flow back into the business to fuel future growth rather than distributing income to shareholders. This strategy is typical for growth-stage biotechnology firms that must preserve capital to fund expensive research and development initiatives. The overall growth and income profile is defined by strong top-line expansion coupled with a complete absence of current dividend income, reflecting a capital-intensive growth strategy typical of the medical device sector.